Plasma myeloperoxidase level and peripheral arterial disease
European Journal of Clinical Investigation, 05/02/2012Haslacher H et al.
The authors suggest consideration of plasma Myeloperoxidase (MPO) for risk stratification of major adverse cardiovascular events in patients with peripheral arterial disease. In contrast, MPO–463G>A is not an independent risk factor for major adverse cardiovascular events in patients suffering from peripheral arterial disease.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.